Client Communication

Change in Instrumentation & Methodology: Vitamin D (Total), 25 OH

Effective February 8, 2024, Clinical Labs of Hawaii (CLH) is pleased to announce a change in the method and analytic platform for Vitamin D, 25 OH (Hydroxyvitamin D, which includes 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3). Testing will be performed on the Elecsys® Vitamin D Total III assay run on the Roche cobas® utilizing a competitive electrochemiluminescence binding assay.

CLH has performed extensive validation studies on the new assay. Benefits include:

- It provides a robust measurement of all sample types, with no restrictions of use in plasma samples.
- It increases the upper reportable range to 240 ng/mL.
- It has negligible cross-reactivity to the 24,25 dihydroxyvitamin D metabolite.
- It is certified by the Centers for Disease Control and Prevention (CDC) for accuracy and precision, assessed by the Vitamin D Standardization Certification Program (VDSCP).
- It is standardized against and is traceable to the National Institute of Standards and Technology Standard Reference material 2972.
- It has an increased biotin tolerance threshold (up to 600 ng/mL), thereby reducing biotin interference for more accurate results.

The change in instrumentation and methodology will not affect the current interpretative ranges used by CLH. All test codes also remain the same:

Vitamin D, 25 OH	
Test code	VITD25 (2718)
Specimen Requirements	1.0 ml (min 0.5 ml) serum from SST or plasma from Lithium Heparin
Reference Range	Pediatric (<17 years) Deficiency <15 ng/mL Insufficiency 15 - 19 ng/mL Sufficiency 20 - 100 ng/mL
	Adult Deficiency <20 ng/mL Insufficiency 20 - 29 ng/mL Sufficiency 30 - 100 ng/mL

If you have any questions, please contact our Client Services Department at 808-677-7998 (Oahu) or 1-866-281-6816 (toll free).

References:

1. Roche Diagnostics, Method Sheet Elecsys® Vitamin D total III, 2022.

Thank you for choosing Clinical Labs of Hawaii.

